natgillin/translations-raw huggingface dataset:
V študijo CLARITY je bilo vključenih 3.491 bolnikov v 12 urah po nastopu akutnega miokardnega infarkta z elevacijo ST spojnice, ki so bili predvideni za trombolitično terapijo. 
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy.
Študija ACTIVE-W je pokazala, da je bilo zdravljenje z antagonisti vitamina K učinkovitejše kot zdravljenje 
The ACTIVE-W study demonstrated that anticoagulant treatment with vitamin K antagonists was more effective than with clopidogrel and ASA.
Krvavitve in hematološke motnje 
Bleeding and haematological disorders
• zaviralce glikoproteina IIb/IIIb (zdravila, ki se uporabljajo za preprečevanje strjevanja krvi). 
• Glycoprotein IIb/IIIa inhibitors (medicines used to stop blood clotting).
Heparin so uporabljali pri več kot 90 % bolnikov in sočasna uporaba heparinske terapije ni pomembno vplivala na relativni delež krvavitev med klopidogrelom in placebom. 
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy.
Kaj je zdravilo Klopidogrel Teva Pharma B.V. in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Teva Pharma B.V. Kako jemati zdravilo Klopidogrel Teva Pharma B.V. 
What Clopidogrel Teva Pharma B.V. is and what it is used for What you need to know before you take Clopidogrel Teva Pharma B.V. How to take Clopidogrel Teva Pharma B.V.
Incidenca večjih krvavitev je bila v obeh skupinah podobna. 
The incidence of major bleeding was similar between groups.
in acetilsalicilno kislino ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot pet dni pred kirurškim posegom. 
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
s klopidogrelom, za katere so na voljo rezultati genotipizacije: CURE (n = 2721), CHARISMA (n = 2428), CLARITY-TIMI 28 (n = 227), TRITON-TIMI 38 (n = 1477) in ACTIVE-A (n = 601), poleg tega pa tudi številne objavljene kohortne študije. 
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Učinkovitost klopidogrela so opazili neodvisno od odmerka acetilsalicilnske kisline (75-325 mg enkrat na dan). 
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily).
Če ste doživeli hudo bolečino v prsih (nestabilna angina ali sršni napad), vam bo morda predpisan klopidogrel v kombinaciji z acetilsalicilno kislino, učinkovino proti bolečinam in za zniževanje zvišane telesne tempreature. 
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed clopidogrel in combination with acetylsalicylic acid, a substance used to relieve pain and lower fever.
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala ali estrogena. 
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital or oestrogen.
Prevelik odmerek bo najverjetneje povečal tveganje za pojav krvavitev. 
An overdose is likely to cause an increased risk of bleeding.
Tako se pri zdravljenju več kot 3 mesece opažena korist v skupini, ki je prejemala klopidogrel in acetilsalicilnsko kislino, ni nadalje povečevala, medtem ko je tveganje za krvavitev ostalo (glejte poglavje 4.4). 
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).
Pri manjših urezninah ali poškodbah, npr. če se urežete ali pri britju, navadno ni razloga za skrb. 
For minor cuts and injuries, e.g. cutting yourself shaving, this is usually of no concern.
ZA SHRANJEVANJE Shranjujte pri temperaturi do 25 ºC. 
Do not store above 25°C.
Farmakodinamična interakcija med klopidogrelom in heparinom je možna in vodi do povečanega tveganja za pojav krvavitev. 
A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding.
Zaviralci agregacije trombocitov brez heparina Oznaka ATC: B01AC04 
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
moklobemid, zdravila za zdravljenje depresije. 
• moclobemide, medicine to treat depression.
Na primer abciksimab, eptifibatid ali tirofiban. 
eptifibatide or tirofiban.
Skupno je 99,7 % bolnikov prejemalo fibrinolitike (fibrinsko specifične: 68,7 %, nefebrinsko specifične: 31,1 %), 89,5 % heparin, 78,7 % blokatorji beta, 54,7 % zaviralce angiotenzinske konvertaze in 63 % statine. 
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
Pediatrična populacija Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte 
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1)
Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (<35 dni), nedavno ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD). 
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Na trgu ni vseh navedenih pakiranj. 
Not all pack sizes may be marketed.
Podatki študije CAPRIE kažejo, da se lahko fenitoin in tolbutamid, ki se presnavljata s CYP2C9, sočasno 
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel.
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4 »Možni neželeni učinki«). 
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible Side Effects')
s 30 tabletami: 30 dni 
• 30 tablets bottle: 30 days
Farmakokinetika digoksina ali teofilina ob sočasni uporabi klopidogrela ni bila spremenjena. 
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel.
V TRITON-TIMI 38 in 3 kohortnih študijah (Collet, Sibbing, Giusti) je imela kombinirana skupina bolnikov, ki so bili ali srednji ali slabi metabolizatorji, večji delež kardiovaskularnih dogodkov (smrt, miokardni infarkt, možganska kap) ali trombozo na žilni opornici kot dobri metabolizatorji. 
In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.
s prikrito krvavitvijo, zlasti prve tedne zdravljenja in/ali po invazivnih kardioloških postopkih ali kirurških posegih. 
Patients should be followed carefully for any signs of bleeding including occult bleeding, especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery.
V celoti je bil klopidogrel v odmerku 75 mg/dan v študiji CAPRIE, primerljiv z acetilsalicilno kislino v odmerku 325 mg/dan, ne glede na starost, spol ali raso. 
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race.
in večkratnih peroralnih odmerkih 75 mg na dan se klopidogrel hitro absorbira. 
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
België/Belgique/Belgien 
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A.
V študiji povečevanja odmerka, ki je zajela 86 novorojenčkov ali dojenčkov, starih do 24 mesecev, s tveganjem tromboze (PICOLO), so klopidogrel ocenili v zaporednih odmerkih 0,01, 0,1 in 0,2 mg/kg pri novorojenčkih 
In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates.
s potrjeno diagnozo pridobljene hemofilije morajo obravnavati in zdraviti zdravniki specialisti, zdravljenje 
Patients with a confirmed diagnosis of acquired haemophilia should be managed and treated by specialists, and clopidogrel should be discontinued.
odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo. 
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
če se urežete ali poškodujete, se lahko krvavitev ustavi počasneje kot običajno. 
If you cut or injure yourself, it may take slightly longer than usual for bleeding to stop.
Če imate ledvično ali jetrno bolezen. 
• You have liver or kidney disease.
Večkratni odmerki po 75 mg na dan tvorijo pomembno zaviranje z ADP sprožene agregacije trombocitov od prvega dne. To se progresivno povečuje in doseže stanje dinamičnega ravnovesja (“steady state”) med 3. 
Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7.
Študija ACTIVE-A (n = 7.554) je bila multicentrična, randomizirana, dvojno slepa, s placebom kontrolirana študija, ki je primerjala klopidogrel 75 mg/dan + acetilsalicilno kislino (n = 3.772) in placebo + acetilsalicilno kislino (n = 3.782). 
The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
Trombotična trombocitopenična purpura (TTP) 
Thrombotic Thrombocytopenic Purpura (TTP)
Glavna merila za nevključitev bolnikov so bila potrjena peptična ulkusna bolezen v preteklih 6 mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov < 50 x 109/l), potreba po klopidogrelu ali peroralnih antikoagulantih ali intoleranca za katero od obeh snovi. 
The major exclusion criteria for patients were documented peptic ulcer disease within the previous 6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 109/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds.
Pojavile so se pri odmerkih, ki so bili vsaj 25-krat večji od odmerkov pri človeku, pri prejemanju kliničnega odmerka 75 mg na dan, in so bile posledica učinka na jetrne presnovne encime. 
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes.
Način uporabe za peroralno uporabo 
Method of administration For oral use
Pri bolnikih, pri katerih ni bila opravljena angiografija, sta bila primarna opazovana dogodka smrt ali ponovni miokardni infarkt do 8. dneva oziroma do odpusta. 
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge.
Če ima bolnik predviden kirurški poseg in antitrombotični učinek začasno ni zaželen, je potrebno zdravljenje 
If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery.
ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97007-0 
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97007-0
Preostale tablete zavrzite 30 dni po odprtju stekleničke. 
Discard any remaining tablets 30 days after first opening of the bottle.
Bolezni sečil glomerulonefritis, zvišanje ravni kreatinina v krvi 
Glomerulonephritis, blood creatinine increased
Preskušanji CLARINET in PICOLO so izvedli z uporabo pripravljene raztopine klopidogrela. 
The CLARINET and the PICOLO trials were conducted using a constituted solution of clopidogrel.
Zaviralci glikoproteina IIb/IIIa: klopidogrel je potrebno uporabljati previdno pri bolnikih, ki se sočasno zdravijo z zaviralci glikoproteina IIb/IIIa (glejte poglavje 4.4). 
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Cmax aktivnega presnovka je po enem 300-mg polnilnem odmerku klopidogrela dvakrat večja kot po štirih dneh uporabe vzdrževalnega odmerka 75 mg. 
The Cmax of the active metabolite is twice as high following a single 300-mg clopidogrel loading dose as it is after four days of 75-mg maintenance dose.
Preostale tablete zavrzite 100 dni po odprtju stekleničke. 
Discard any remaining tablets 100 days after first opening of the bottle.
filmsko obložena tableta 
Film-coated tablet.
Farmakogenetika: Pri bolnikih, ki so slabi metabolizatorji CYP2C19, med uporabo priporočenih odmerkov klopidogrela nastane manj aktivnega presnovka klopidogrela in ima manjši učinek na delovanje trombocitov. 
Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function.
s preiskavami krvi ali urina. 
This may be detectable via blood or urine tests.
Pri zdravljenju tega stanja vam je zdravnik v zamašeno ali zoženo arterijo morda moral vstaviti stent (žično opornico), da bi žilo tako razširil in obnovil pretok krvi. 
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow.
s pogostnostjo “neznani”. 
* Information related to clopidogrel with frequency “not known”.
Jedro tablete laktoza monohidrat mikrokristalna celuloza hidroksipropil celuloza (E463) krospovidon (tip A) hidrogenirano ricinusovo olje natrijev lavrilsulfat 
Lactose monohydrate Cellulose, microcrystalline Hydroxypropylcellulose (E463) Crospovidone (type A) Hydrogenated castor oil Sodium laurilsulfate
Tabelarični seznam neželenih učinkov 
Tabulated list of adverse reactions
Incidenca klinično pomembnih krvavitev je bila podobna tisti, ki so jo opazili pri uporabi trombolitikov in heparina sočasno z acetilsalicilno kislino (glejte poglavje 4.8). 
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8).
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
so po uporabi klopidogrela poročali zelo redko, včasih po kratki izpostavljenosti. 
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
Zdravnik vam bo moral predpisati tudi acetilsalicilno kislino (učinkovina proti bolečinam in za zniževanje zvišane telesne tempreature, kakor tudi za preprečevanje strjevanja krvi). 
You should also be given acetylsalicylic acid (a substance used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor.
Teva Pharma B.V., Computerweg 10, 3542 DR Utrecht, Nizozemska 
Computerweg 10, 3542 DR Utrecht, The Netherlands
Zdravilo Klopidogrel Teva Pharma B.V. morate jemati vse dokler vam ga vaš zdravnik predpisuje. 
You should continue taking Clopidogrel Teva Pharma B.V. for as long as your doctor has told you to take it.
s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije. 
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Q zobca, nizka do visoka raven tveganja, diabetes, potreba po revaskularizaciji, starost, spol, itd), so skladni z rezultati primarne analize. 
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
Kaj je zdravilo Klopidogrel Teva Pharma B.V. in za kaj ga uporabljamo 
What Clopidogrel Teva Pharma B.V. is and what it is used for
o če ste imeli pred kratkim kirurški poseg ali načrtujete kirurški poseg (vključno z o če imate kakršnokoli krvno motnjo, zaradi katere ste bolj nagnjeni k notranji krvavitvi o če imate kakršnokoli bolezen, zaradi katere ste bolj nagnjeni k notranji krvavitvi (npr. 
For example: o If you have recently suffered from a serious injury o If you have recently undergone surgery or are due to have surgery (including dental surgery) o If you have any blood disorder which makes internal bleeding (bleeding inside your body) more likely o If you suffer from any other illness which makes internal bleeding more likely (e.g. stomach ulcers or wounds inside the eye)
resno obolenje, ki se imenuje trombotična trombocitopenična purpura (redka motnja strjevanja krvi, ki povzroči pojav številnih krvnih strdkov po celem telesu). 
A serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body).
CYP2C19 je vključen tako v nastajanje aktivnega presnovka kot vmesnega presnovka, 2oksoklopidogrela. 
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
in/ali hematološko reakcijo na enega od tienopiridinov, imajo lahko večje tveganje za pojav enake ali druge reakcije na drug tienopiridin. 
Patients who had developed a previous allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
omeprazol, esomeprazol ali cimetidin, zdravila za zdravljenje težav z želodcem, 
• Omeprazole, esomeprazole or cimetidine, medicines to treat upset stomach.
Preveliki odmerki klopidogrela lahko podaljšajo čas krvavitve in posledično povzročijo zaplete 
Overdose following clopidogrel administration may lead to prolonged bleeding time and subsequent bleeding complications.
Koristi, ki so jih opazili pri uporabi klopidogrela, so bile neodvisne od drugih akutnih in dolgotrajnih srčnožilnih terapij (kot je heparin /nizkomolekularni heparin, antagonisti glikoproteina IIb/IIIa, učinkovine za zniževanje lipidov, blokatorji beta in zaviralci angiotenzinske konvertaze). 
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
Pri bolnikih, ki so ostali na zdravljenju do pet dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6 % za klopidogrel v kombinaciji z acetilsalicilno kislino in 6,3 % za placebo v kombinaciji z acetilsalicilno kislino. 
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.
flukonazol, vorikonazol, ciprofloksacin ali klorampfenikol, zdravila za zdravljenje bakterijskih in glivičnih okužb, 
• Fluconazole, voriconazole, ciprofloxacin, or chloramphenicol, medicines to treat bacterial and fungal infections.
Preostale tablete je potrebno odstraniti po preteku 
Any remaining tablets should be discarded at the end of this period.
Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna. 
Risk Management Plan (RMP)
Sočasna uporaba z zdravilom Klopidogrel Teva Pharma B.V. ni priporočena. 
Their use with Clopidogrel Teva Pharma B.V. is not recommended.
Pri bolnikih z akutnim koronarnim sindromom: 
• Adult patients suffering from acute coronary syndrome:
Imetnik dovoljenja za promet z zdravilom in izdelovalci 
Marketing Authorisation Holder and Manufacturer
peroralne koagulanse (zdravila, ki se uporabljajo za preprečevanje strjevanja krvi), kot je varfarin. 
• Oral anticoagulants (oral medicines used to stop blood clotting) such as warfarin.
Zdravilo vsebuje tudi laktozo in hidrogenirano ricinusovo olje. 
LIST OF EXCIPIENTS It also contains lactose and hydrogenated castor oil.
Krvavitev se lahko pojavi kot krvavitev iz želodca ali črevesja, kot odrgnine, hematomi (neobičajne krvavitve ali odrgnine pod kožo), krvavitev iz nosu, kri v urinu. 
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleeds or blood in the urine.
Psihiatrične motnje halucinacije, zmedenost 
Hallucinations, confusion
Zanjo je značilna trombocitopenija in mikroangiopatična hemolitična anemija, povezana ali z nevrološkimi spremembami, motnjo v delovanju ledvic ali povišano telesno temperaturo. 
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever.
V primeru opaženih krvavitev je potrebno razmisliti o uvedbi ustreznega zdravljenja. 
Appropriate therapy should be considered if bleedings are observed.
Bolniki so bili naključno razdeljeni v skupine, ki so prejemale klopidogrel 75 mg/dan ali acetilsalicilno kislino 325 mg/dan, spremljali so jih od 1 do 3 let. 
Patients were randomised to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
takoj preučiti potrebo po določanju števila krvnih celic in/ali drugih ustreznih preiskav, kadar se v obdobju zdravljenja pojavijo klinični simptomi, ki nakazujejo krvavitev (glejte poglavje 4.8). 
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).
Incidenca hujših primerov je bila podobna za klopidogrel in za acetilsalicilno kislino. 
The incidence of severe cases was similar for clopidogrel and ASA.
in in vivo presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami in povzroči hidrolizo v neaktiven karboksilnokislinski derivat (85 % presnovkov v obtoku), druga pa z več encimi citokroma P450. 
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Zaviralci protonske črpalke (PPI): 
Proton Pump Inhibitors (PPI):
ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji. 
Clopidogrel has no or negligible influence on the ability to drive and use machines.
Madžarska 
Hungary
Iz previdnosti naj sočasno ne bi uporabljali močnih ali srednje močnih zaviralcev CYP2C19 (za seznam zaviralcev CYP2C19 glejte poglavje 4.5; glejte tudi poglavje 5.2). 
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
če imate hudo jetrno obolenje. 
• If you have severe liver disease.
Klopidogrel je v primerjavi z acetilsalicilno kislino značilno zmanjšal incidenco novih ishemičnih dogodkov (sestavljen opazovani dogodek miokardni infarkt, ishemična kap in žilna smrt). 
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA.
Encimi CYP450 morajo presnoviti klopidogrel, da nastane aktivni presnovek, ki zavira agregacijo trombocitov. 
Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.